Suchergebnisse - "Hulse, Michael"

PubPharm (50)

1

PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies

enthalten in: Cancer research communications | 2023

von Carter, J. | Hulse, M. | Sivakumar, M. | +11

2

Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer

enthalten in: Nature cancer | 2023

von Miller, K. | O'Connor, S. | Pniewski, K. | +17

3

The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity

enthalten in: Nature communications | 2022

von Morgan, S. | Tanizawa, H. | Caruso, L. | +8

4

Epstein–Barr virus-encoded latent membrane protein 1 and B-cell growth transformation induces lipogenesis through fatty acid synthase

enthalten in: bioRxiv.org | 2021

von Hulse, M. | Johnson, S. | Boyle, S. | +2

5

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

enthalten in: Cancer research | 2021

von Maifrede, S. | Le, B. | Nieborowska-Skorska, M. | +32

6

Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and B-Cell Growth Transformation Induce Lipogenesis through Fatty Acid Synthase

enthalten in: Journal of virology | 2021

von Hulse, M. | Johnson, S. | Boyle, S. | +2

7

Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1

enthalten in: PLoS pathogens | 2018

von Hulse, M. | Caruso, L. | Madzo, J. | +3

8

PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type

enthalten in: Journal of virology | 2018

von Lupey-Green, L. | Caruso, L. | Madzo, J. | +4

9

Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage

enthalten in: Oncotarget | 2018

von Caruso, L. | Martin, K. | Lauretti, E. | +6

10

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs

enthalten in: Blood advances | 2017

von Maifrede, S. | Martinez, E. | Nieborowska-Skorska, M. | +8

1
2
3
4
5
Nächster »
[5]